Univariate analyses of CNS relapse among propensity score matched patients
| Characteristic . | Overall n = (358) . | CNS relapse (n = 19) . | No CNS relapse (n = 339) . | P . |
|---|---|---|---|---|
| Prophylaxis route, n (%) | ||||
| Intrathecal | 179 (50) | 9 (5.0) | 170 (95.0) | .81 |
| HD-MTX | 179 (50) | 10 (5.6) | 169 (94.4) | |
| CNS-IPI, n (%) | ||||
| 0-1 (low) | 79 (22.1) | 5 (6.5) | 72 (93.5) | .10 |
| 2-3 (moderate) | 177 (49.4) | 5 (2.8) | 172 (97.2) | |
| ≥4 (high) | 100 (27.9) | 9 (8.7) | 95 (91.3) | |
| NCCN-IPI, n (%) | ||||
| Low | 27 (7.5) | 0 (0) | 27 (100) | .37 |
| Low-Int | 154 (43.0) | 8 (5.2) | 146 (94.8) | |
| High-Int | 149 (41.6) | 8 (5.4) | 141 (94.6) | |
| High | 28 (7.8) | 3 (10.7) | 25 (89.3) | |
| Double-hit positive | 30 (8.4) | 2 (6.7) | 28 (93.3) | .86 |
| Characteristic . | Overall n = (358) . | CNS relapse (n = 19) . | No CNS relapse (n = 339) . | P . |
|---|---|---|---|---|
| Prophylaxis route, n (%) | ||||
| Intrathecal | 179 (50) | 9 (5.0) | 170 (95.0) | .81 |
| HD-MTX | 179 (50) | 10 (5.6) | 169 (94.4) | |
| CNS-IPI, n (%) | ||||
| 0-1 (low) | 79 (22.1) | 5 (6.5) | 72 (93.5) | .10 |
| 2-3 (moderate) | 177 (49.4) | 5 (2.8) | 172 (97.2) | |
| ≥4 (high) | 100 (27.9) | 9 (8.7) | 95 (91.3) | |
| NCCN-IPI, n (%) | ||||
| Low | 27 (7.5) | 0 (0) | 27 (100) | .37 |
| Low-Int | 154 (43.0) | 8 (5.2) | 146 (94.8) | |
| High-Int | 149 (41.6) | 8 (5.4) | 141 (94.6) | |
| High | 28 (7.8) | 3 (10.7) | 25 (89.3) | |
| Double-hit positive | 30 (8.4) | 2 (6.7) | 28 (93.3) | .86 |
All listed P values are 2-sided.
CNS, central nervous system; HD, high dose; IPI, international prognostic index; MTX, methotrexate; NCCN, National Comprehensive Cancer Network.